| Underwriter | Biotechnology Company | Date priced | Offering price per share** | 8/29/08 Share Price | Offering Gross (M)** | After-Market Performance (%) |
| Banc of America Securities | Allos Therapeutics Inc. (ALTH) | 5/23 | $5.64 | $9.33 | $69.9 | +65% |
| Canaccord Adams Inc. | La Jolla Pharmaceutical Co. (LJPC) | 5/7 | $1.92 | $1.77 | $30 | -8% |
| Orexigen Therapeutics Inc. (OREX) | 1/24 |
$11 |
$11.63 |
$80.6 |
+6% |
|
| Citigroup Global Markets | Allos Therapeutics Inc.(ALTH) | 5/23 | $5.64 | $9.33 | $69.9 | +65% |
| Cowen & Co. | Acorda Therapeutics Inc.(ACOR) | 2/13 | $21.50 | $28.15 | $81.6 | +31% |
| Credit Suisse Securities | Rigel Pharmaceuticals Inc. (RIGL) (lead) | 2/1 | $27 | $23.66 | $135 | -12% |
| Dawson James Securities | Bioheart Inc. (BHRT) (IPO; lead) | 2/20 | $5.25 | $4.11 | $5.8 | -22% |
| Deutsche Bank Securities | Acorda Therapeutics Inc. (ACOR) (co-lead) | 2/13 | $21.50 | $28.15 | $81.6 | +31% |
| Acorda Therapeutics Inc. (ACOR (lead) | 8/7 | $28.50 | $28.15 |
$131.1
|
-1% | |
| Targacept Inc. (TRGT) (lead) | 1/17 |
$7.07 |
$9.15 |
$30.9 |
+29% |
|
| Friedman Billings Ramsey | Acorda Therapeutics Inc. (ACOR) | 2/13 | $21.50 | $28.15 | $81.6 | +31% |
| Goldman Sachs & Co. | Illumina Inc. (ILMN) (lead) | 8/7 | $87.50 | $86.13
|
$306.25 | -2% |
| Incyte Corp.(INCY) (lead) | 8/7 | $9 | $10.23 |
$108.68
|
+14% | |
| Theravance Inc. (THRX) | 1/17 | $25.87 | $13.63
|
$172.5
|
-47%
|
|
Vertex Pharmaceuticals Inc. (VRTX) |
2/13 |
$17.14 |
$26.86 |
$405.8 |
+57% |
|
| GunnAllen Financial | Opexa Therapeutics Inc. (OPXA) (co-lead) | 2/14 | $2 | $2.07 | $7.6 | +4% |
| Jefferies & Co. Inc. | Rigel Pharmaceuticals Inc. (RIGL) | 2/1 | $27 | $23.66 | $135 | -12% |
| JMP Securities LLC | Orexigen Therapeutics Inc. (OREX) | 1/24 | $11 | $11.63 | $80.6 | +6% |
| JP Morgan Securities | Acorda Therapeutics Inc. (ACOR) (co-lead) | 2/13 | $21.50 | $28.15 | $81.6 | +31%
|
| Biodel Inc. (BIOD) (co-lead) | 2/7 | $15.50 | $17.87 | $50.53 | +15% | |
| Incyte Corp (INCY) | 8/7 | $9 | $10.23 | $108.68 | +14% | |
Luminex Corp. (LMNX) (co-lead) |
6/25 | $19.91 | $25.49 |
$80.14 |
+28% | |
| Seattle Genetics Inc. (SGEN) (co-lead) | 1/18 | $9 | $11.15 | $103.5 | +24% | |
Vertex Pharmaceuticals Inc. (VRTX) |
2/13 |
$17.14 |
$26.86 |
$405.8 |
+57% |
|
| Lazard Capital Markets | Acorda Therapeutics Inc. (ACOR) | 2/13 | $21.50 | $28.15 | $81.6 | +31% |
| Orexigen Therapeutics Inc. (OREX) | 1/24 | $11 | $11.63 | $80.6 | +6% | |
| Sequenom Inc. (SQNM) | 6/26 | $15.50 | $22.73 |
$98.04 |
+47% | |
| Targacept Inc.(TRGT) |
1/17 |
$7.07 | $9.15 |
$30.9 |
+29% |
|
| Leerink Swann LLC | Biodel Inc. (BIOD)
|
2/7 | $15.50 | $17.87 | $50.53 | +15%
|
| Orexigen Therapeutics Inc. (OREX) (co-lead) | 1/24 |
$11 | $11.63 | $80.6 |
+6% | |
| Sequenom Inc. (SQNM) | 6/26 | $15.50 | $22.73 | $98.04 | +47% | |
| Lehman Brothers Inc. | Sequenom Inc. (SQNM) (co-lead) | 6/26 | $15.50 | $22.73 | $98.04 | +47% |
| MDB Capital Group LLC | Opexa Therapeutics Inc. (OPXA) (co-lead) | 2/14 | $2 | $2.07 | $7.6 | +4% |
| Merrill Lynch & Co. | Allos Therapeutics Inc. (ALTH) (lead) | 5/23 | $5.64 | $9.33 | $69.9
|
+65% |
| Orexigen Therapeutics Inc. (OREX) (co-lead) | 1/24 | $11 |
$11.63 |
$80.6
|
+6% | |
| Theravance Inc. (THRX) (lead) | 1/17 | $25.87 | $13.63 | $172.5 | -47% | |
| Vertex Pharmaceuticals Inc. (VRTX) (lead) | 2/13 |
$17.14 |
$26.86 |
$405.8 |
+57% |
|
| Morgan Stanley & Co. | Biodel Inc. (BIOD) (co-lead) | 2/7 | $15.50 | $17.87 | $50.53 | +15% |
Incyte Corp (INCY) |
8/7 | $9 |
$10.23 | $108.68 | +14% | |
| Vertex Pharmaceuticals Inc. (VRTX) | 2/13 | $17.14 | $26.86 | $405.8 | +57% | |
| Natixis Bleichroeder Inc. | Biodel Inc. (BIOD) | 2/7 | $15.50 | $17.87 | $50.53 | +15%
|
| Orexigen Therapeutics Inc. (OREX) |
1/24 |
$11 |
$11.63 |
$80.6 |
+6% |
|
| Needham & Co. | Seattle Genetics Inc. (SGEN) | 1/18 | $9 | $11.15 | $103.5 | +24% |
| Oppenheimer & Co. Inc. | Rigel Pharmaceuticals Inc. (RIGL)
|
2/1 | $27 | $23.66 | $135
|
-12% |
| Sequenom Inc. (SQNM) | 6/26 |
$15.50 | $22.73 | $98.04 |
+47% | |
| Targacept Inc. (TRGT) | 1/17 | $7.07 | $9.15 | $30.9 | +29% | |
| Pacific Growth Equities | Targacept Inc. (TRGT) | 1/17 | $7.07 | $9.15 | $30.9 | +29% |
| Piper Jaffray | Acorda Therapeutics Inc. (ACOR) | 2/13 | $21.50 | $28.15 | $81.6 | +31% |
| RBC Capital Markets | Seattle Genetics Inc. (SGEN) | 1/18 | $9 | $11.15 | $103.5 | +24% |
| Rodman & Renshaw | Epicept Corp. (EPCT) (lead) Sequenom Inc. (SQNM) |
3/6 6/26 |
$0.92 $15.50 |
$0.63 $22.73 |
$4.97 $98.04 |
-32% +47% |
| Thomas Weisel Partners | Rigel Pharmaceuticals Inc. (RIGL) | 2/1 | $27 | $23.66 | $135 | -12% |
| UBS Investments | La Jolla Pharmaceutical Co. (LJPC) (lead) | 5/7 | $1.92 |
$1.77
|
$30
|
-8% |
| Luminex Corp. (LMNX) (co-lead) | 6/25 |
$19.91
|
$25.49 | $80.14 | +28% | |
Seattle Genetics Inc. (SGEN) (co-lead) |
1/18 |
$9 | $11.15 | $103.5 | +24% | |
Sequenom Inc. (SQNM) (co-lead) |
6/26 |
$15.50 |
$22.73 |
$98.04 |
+47% |
|
| William Blair & Co. LLC | Seattle Genetics Inc. (SGEN) | 1/18 | $9 | $11.15 | $103.5 | +24% |
|
Notes: * The financings in this chart are for public offerings in the U.S. only. The data were compiled primarily from BioWorld Financial Watch's monthly financing charts covering the period from Jan. 1 to Aug. 31, 2008. Those charts were published on Feb. 4, March 10, April 7, May 5, June 9, July 7 and Aug. 4, 2008. The gross proceed totals listed reflect only those shares sold by companies. They include money raised through overallotment options, when disclosed. ** All prices in U.S. dollars. Offering price per share is adjusted to reflect any post-offering splits. Unless otherwise noted, shares are traded on the Nasdaq exchange.IPO = Initial Public Offering | ||||||
